The Myelin Disorders Biorepository Project (MDBP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03047369 |
|
Recruitment Status :
Recruiting
First Posted : February 9, 2017
Last Update Posted : January 9, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.
Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.
| Condition or disease |
|---|
| Leukodystrophy White Matter Disease Leukoencephalopathies Aicardi Goutieres Syndrome Metachromatic Leukodystrophy TUBB4A-Related Leukodystrophy 4H Syndrome Krabbe Disease Alexander Disease Pelizaeus-Merzbacher Disease Adrenoleukodystrophy Adrenomyeloneuropathy Multiple Sulfatase Deficiency Megalencephalic Leukoencephalopathy With Subcortical Cysts Vanishing White Matter Disease Cockayne Syndrome Labrune Syndrome ADLD Gangliosidoses Peroxisomal Biogenesis Disorder Adult-Onset Leukodystrophy With Neuroaxonal Spheroids Hereditary Diffuse Leukoencephalopathy With Spheroids |
Genetic white matter disorders (leukodystrophies) are estimated to have an incidence of approximately 1:7000 live births. In the past, patients with white matter disease of unknown cause evaluated by the investigator achieved a diagnosis in fewer than 46% of cases after extensive conventional clinical testing. Even when a diagnosis is achieved, the diagnosis takes an average of eight years and this "odyssey" results in testing charges to patients and insurers in excess of $8,000 on average per patient, including patients who never achieve a diagnosis at all. With next generation approaches such as whole exome sequencing, the diagnostic efficacy is closer to 70%, but approximately a third of individuals do not achieve a specific etiologic diagnosis. These diagnostic challenges represent an urgent and unresolved gap in knowledge and disease characterization, as obtaining a definitive diagnosis is of paramount importance for leukodystrophy patients.
Moreover, the mechanisms of disease in many leukodystrophies of known cause are very poorly understood, with little known about the best symptomatic management and, thus, limited standards of care are available for the management of these patients.
The purpose of this study is to: (Aim 1) Define novel homogeneous groups of patients with unclassified leukodystrophy and work toward finding the cause of these disorders; (Aim 2) assess the validity and utility of next-generation sequencing in the diagnosis of leukodystrophies; (Aim 3) establish disease mechanisms in selected known leukodystrophies; (Aim 4) track current care and natural history of these patients to define the longitudinal course and determinants of outcomes in these disorders; (Aim 5) contact subjects for future research studies and/or clinical programs.
This biorepository will use available basic science and clinical research approaches to establish novel diagnoses, biomarkers, and outcome measures for future clinical diagnostic and therapeutic approaches.
| Study Type : | Observational [Patient Registry] |
| Estimated Enrollment : | 12000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 10 Years |
| Official Title: | The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network |
| Actual Study Start Date : | December 8, 2016 |
| Estimated Primary Completion Date : | December 8, 2030 |
| Estimated Study Completion Date : | December 8, 2030 |
- Define Novel Homogeneous Groups of Patients with Unclassified Leukodystrophy [ Time Frame: 01/08/2016 - 01/08/2026 ]In patients with an unclassified leukodystrophy, the study team will collect as much information as available from existing medical records including existing clinical evaluations, neuropsychological/rehabilitation evaluations, and results from blood, urine, spinal fluid, radiological, and peripheral tissue pathological tests. This data will be evaluated to create nosologic groups amongst patients with unclassified leukodystrophy. Additionally, this aim includes the collection and long-term banking of biological samples in subjects with classified and unclassified leukodystrophies to develop a biorepository. These samples will be compared to samples collected from control subjects, either collected directly from enrolled subjects or through existing banked biological samples.
- Assess Validity of Next-Generation Sequencing in the Diagnosis of Leukodystrophies [ Time Frame: 01/08/2016 - 01/08/2026 ]Unclassified leukodystrophy patients enrolled in this study may undergo next generation sequencing approaches, including research whole exome sequencing (WES), whole genome sequencing (WGS), RNA sequencing and high throughput genomics analysis in parallel to standard clinical testing to achieve novel molecular classifications.
- Assess Utility of Next-Generation Sequencing in the Diagnosis of Leukodystrophies [ Time Frame: 01/08/2016 - 01/08/2026 ]Clinical utility defined as changes in care and clinical state, included changes in medical morbidities, surgeries, pharmacologic management of complications and implementation of disease specific therapies.
- Track Current Care of Leukodystrophy Patients [ Time Frame: 01/08/2016 - 01/08/2026 ]Includes a longitudinal collection of clinical data on diagnostic and therapeutic interventions in leukodystrophy patients and related controls.
- Track Natural History of Leukodystrophy Patients [ Time Frame: 01/08/2016 - 01/08/2026 ]Includes longitudinal collection of clinical data on disease presentation, progression and morbidities.
- Establish Disease Mechanisms in Leukodystrophies [ Time Frame: 01/08/2016 - 01/08/2026 ]Specific leukodystrophies will be selected for further mechanistic study, using clinical and laboratory tools to establish increased understanding of the underlying pathophysiology. The over-riding hypothesis of this aim is that integrated biochemical, genomic, metabolic, histologic and immunologic profiles of patients with leukodystrophy will define downstream pathway changes consistent with primary defects causing white matter disease. Appropriate controls will be used for comparison to disease related samples.
- Contact for Future Research Studies and/or Clinical Programs [ Time Frame: 01/08/2016 - 01/08/2026 ]Individuals enrolled in the study may be informed of other research studies, either at the Children's Hospital of Philadelphia or another site affiliated or not affiliated with this study, that may be of interest to them and/or their their families based on a specific diagnosis or lack thereof.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria (Affected Subjects):
- Male or female of any age;
- Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems;
- Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;
- Willingness to provide clinical data, participate in standardized assessments, and/or provide biologic samples.
Exclusion Criteria (Affected Subjects)
- Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;
- Inability to provide consent.
Inclusion Criteria (Healthy Controls)
- Male or female of any age;
- Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain;
- Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.
Exclusion Criteria (Healthy Controls)
- Inability to provide consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03047369
| Contact: Omar S. Sherbini, MPH | 215-590-3068 | sherbinio@chop.edu |
| United States, California | |
| Stanford University (Lucile Packard Children's Hospital) | Recruiting |
| Palo Alto, California, United States, 94304 | |
| Contact: Keith Van Haren, MD | |
| United States, District of Columbia | |
| Children's National Medical Center | Recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: Jamie Fraser, MD, PhD | |
| United States, Georgia | |
| Emory University (Children's Healthcare of Atlanta) | Recruiting |
| Atlanta, Georgia, United States, 30342 | |
| Contact: Stephanie Keller, MD | |
| United States, Maryland | |
| Kennedy Krieger Institute | Recruiting |
| Baltimore, Maryland, United States, 21205 | |
| Contact: Ali Fatemi, MD, MBA | |
| United States, Massachusetts | |
| Massachusetts General Hospital (MGH) | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Contact: Florian Eichler, MD | |
| United States, Pennsylvania | |
| The Children's Hospital of Philadelphia | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Omar Sherbini, MPH 215-590-3068 sherbinio@chop.edu | |
| Principal Investigator: Adeline Vanderver, MD | |
| Sub-Investigator: Laura Adang, MD, PhD, MSTR | |
| Sub-Investigator: Amy Waldman, MD, MSCE | |
| University of Pennsylvania | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Jennifer Orthmann-Murphy, MD, PhD | |
| United States, Texas | |
| Baylor College of Medicine (Texas Children's Hospital) | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Lisa Emrick, MD | |
| United States, Utah | |
| University of Utah (Primary Children's Hospital) | Recruiting |
| Salt Lake City, Utah, United States, 84112 | |
| Contact: Joshua Bonkowsky, MD, PhD | |
| Principal Investigator: | Adeline Vanderver, MD | Children's Hospital of Philadelphia |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Adeline Vanderver, MD, Program Director, Leukodystrophy Center, Children's Hospital of Philadelphia |
| ClinicalTrials.gov Identifier: | NCT03047369 |
| Other Study ID Numbers: |
14-011236 U54NS115052 ( U.S. NIH Grant/Contract ) U01NS106845 ( U.S. NIH Grant/Contract ) |
| First Posted: | February 9, 2017 Key Record Dates |
| Last Update Posted: | January 9, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | IPD will be made available to researchers, sponsors, and other stakeholders. Data Use Agreement (DUA) must be put in place with any recipient of IPD. Only aggregate data will be shared publicly. |
| Time Frame: | IPD may be shared at any time. |
| Access Criteria: | Only aggregate data will be shared publicly. Please contact a member of the central study team for information regarding the release of IPD. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
leukodystrophy white matter disease leukoencephalopathy |
myelin demyelinating mdbp |
|
Cockayne Syndrome Adrenoleukodystrophy Leukoencephalopathies Gangliosidoses Leukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Pelizaeus-Merzbacher Disease Alexander Disease Multiple Sulfatase Deficiency Disease Peroxisomal Disorders Syndrome Disease Pathologic Processes Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Hereditary Central Nervous System Demyelinating Diseases Demyelinating Diseases Mental Retardation, X-Linked Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolism, Inborn Errors Metabolic Diseases Adrenal Insufficiency |